Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies

SIMPLE SUMMARY: The treatment of B cell malignancies was transformed by the development of a monoclonal antibody—rituximab—that targets CD20, a protein expressed on the surface of B cells. However, some types of B cell malignancies do not express CD20 or can reduce the expression of the protein to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharyya, Puja, Christopherson, Richard I., Skarratt, Kristen K., Chen, Jake Z., Balle, Thomas, Fuller, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251933/
https://www.ncbi.nlm.nih.gov/pubmed/37296844
http://dx.doi.org/10.3390/cancers15112881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251933/
https://www.ncbi.nlm.nih.gov/pubmed/37296844
http://dx.doi.org/10.3390/cancers15112881

Ejemplares similares